KORU Medical Systems (KRMD) Projected to Post Quarterly Earnings on Thursday

KORU Medical Systems (NASDAQ:KRMD) is projected to post its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.90 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

KORU Medical Systems Price Performance

NASDAQ:KRMD opened at $4.85 on Thursday. KORU Medical Systems has a 12 month low of $1.86 and a 12 month high of $6.61. The stock has a 50 day moving average of $5.31 and a two-hundred day moving average of $4.78. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01. The firm has a market cap of $224.65 million, a P/E ratio of -60.63 and a beta of 0.47.

Analysts Set New Price Targets

KRMD has been the subject of several research reports. Craig Hallum reiterated a “buy” rating and set a $7.00 price target on shares of KORU Medical Systems in a research report on Tuesday, January 13th. Canaccord Genuity Group upped their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Finally, Lake Street Capital upped their price objective on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, KORU Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $6.13.

Hedge Funds Weigh In On KORU Medical Systems

A number of institutional investors have recently bought and sold shares of KRMD. BNP Paribas Financial Markets lifted its stake in shares of KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after purchasing an additional 3,478 shares during the last quarter. Lazard Asset Management LLC purchased a new position in KORU Medical Systems in the second quarter valued at $59,000. Occudo Quantitative Strategies LP acquired a new position in KORU Medical Systems during the 4th quarter worth $127,000. Invesco Ltd. acquired a new position in shares of KORU Medical Systems during the second quarter worth about $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in KORU Medical Systems in the second quarter valued at approximately $83,000. 58.60% of the stock is owned by hedge funds and other institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.